| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on July 5, 2004
Accepted on December 2, 2004
Review |
1 Department of Nuclear Medicine, St. Vincent's University Hospital, Dublin, Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin and Dublin Molecular Medicine Centre, Dublin 4, Ireland
Background: Unpredictable efficacy and toxicity are hallmarks of most anticancer therapies Predictive markers are factors that are associated with response or resistance to a particular therapy.
Methods: The English literature relating to predictive markers in oncology was reviewed. Particular attention was paid to metaanalyses, systematic reviews, prospective trials, and guidelines issued by expert panels.
Results: The prototype predictive tests in oncology are the estrogen receptor (ER) and progesterone receptors (PR), which are used to select patients with breast cancer likely to respond to hormone therapy. A more recently introduced predictive marker is HER-2 for selecting patients with advanced breast cancer for treatment with the therapeutic antibody trastuzumab (Herceptin). In adjuvant breast cancer, overproduction of HER-2 may also indicate an enhanced sensitivity to high-dose anthracycline-based regimens. On the other hand, in both early and advanced breast cancer, high concentrations of HER-2 appear to correlate with a lower probability of response to hormone therapy. Although many different anticancer drugs appear to mediate tumor regression by inducing apoptosis, there is currently no consistent evidence that any of the molecules implicated in this process can be used as predictive markers.
Conclusions: Currently, the only recommended predictive markers in oncology are ER and PR for selecting endocrine-sensitive breast cancers and HER-2 for identifying breast cancer patients with metastatic disease who may benefit from trastuzumab. For malignancies other than breast cancers, validated predictive markers do not exist at present.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. Palijan, I. Fernandes, M. Verway, M. Kourelis, Y. Bastien, L. E. Tavera-Mendoza, A. Sacheli, V. Bourdeau, S. Mader, and J. H. White Ligand-dependent Corepressor LCoR Is an Attenuator of Progesterone-regulated Gene Expression J. Biol. Chem., October 30, 2009; 284(44): 30275 - 30287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J. Clin. Pathol., January 1, 2008; 61(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cronin, C. Sangli, M.-L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K. C. Langone, and D. Watson Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer Clin. Chem., June 1, 2007; 53(6): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Cardone, A. Bellizzi, G. Busco, E. J. Weinman, M. E. Dell'Aquila, V. Casavola, A. Azzariti, A. Mangia, A. Paradiso, and S. J. Reshkin The NHERF1 PDZ2 Domain Regulates PKA-RhoA-p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells Mol. Biol. Cell, May 1, 2007; 18(5): 1768 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakagawa, S. K. Huang, S. R. Martinez, A. N. Tran, D. Elashoff, X. Ye, R. R. Turner, A. E. Giuliano, and D. S.B. Hoon Proteomic Profiling of Primary Breast Cancer Predicts Axillary Lymph Node Metastasis Cancer Res., December 15, 2006; 66(24): 11825 - 11830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy Serum Tumor Markers in Breast Cancer: Are They of Clinical Value? Clin. Chem., March 1, 2006; 52(3): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Jung, H. S. Park, I. J. Lee, H. Namkoong, S. M. Shin, G. W. Cho, S.-A. Ha, Y. G. Park, Y. S. Lee, J. Ko, et al. The HCCR Oncoprotein as a Biomarker for Human Breast Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7700 - 7708. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
